<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02875561</url>
  </required_header>
  <id_info>
    <org_study_id>16-0701.cc</org_study_id>
    <nct_id>NCT02875561</nct_id>
  </id_info>
  <brief_title>Ultrasonic Aspiration Versus CO2 Laser Ablation for the Treatment of Vulvar Intraepithelial Neoplasia</brief_title>
  <official_title>A Randomized Controlled Trial of Ultrasonic Aspiration Versus CO2 Laser Ablation for the Treatment of Vulvar Intraepithelial Neoplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stryker Instruments</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the incidence of vulva dysplasia&#xD;
      recurrence within 12 months of treatment with Carbon Dioxide (CO2) laser ablation or&#xD;
      ultrasonic aspiration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Incidence of Vulvar Intraepithelial Neoplasia (VIN) is increasing among women and there still&#xD;
      lacks a standard of care for optimal treatment. Current treatment options aim to treat the&#xD;
      symptoms associated with VIN and result in a high recurrence rate. Due to the high&#xD;
      reoccurrence rate and the nature of the current treatments, a more effective treatment option&#xD;
      is warranted. An effective treatment that targets only the diseased areas could potentially&#xD;
      decrease recurrence rates. Additionally, a more conservative treatment modality could&#xD;
      contribute to reduced risks of scarring, discomfort, and psychosocial and sexual distraught.&#xD;
      The researchers hypothesize that treatment for VIN with ultrasonic aspiration will have a 60%&#xD;
      reduction in recurrence rates over 12 months as compared to CO2 laser aspiration.&#xD;
&#xD;
      This study will employ a randomized controlled trial (RCT) design. This is a phase III study&#xD;
      to determine the effectiveness of a more targeted treatment therapy for VIN (comparing&#xD;
      ultrasonic aspiration versus CO2 laser ablation). Potential participants will be identified&#xD;
      through the gynecological clinical practices following diagnosis of high grade VIN and will&#xD;
      be randomized (1:1) to one of the treatment therapies. Randomization will be stratified for&#xD;
      multi-focal disease and Human Papillomavirus (HPV) status. Both the Sonopet Ultrasonic&#xD;
      Aspirator and the CO2 laser ablation devices are FDA approved devices for the treatment of&#xD;
      vulvar dysplasia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of recurrence of dysplasia</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of recurrence of dysplasia time point 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of pain</measure>
    <time_frame>10 days</time_frame>
    <description>Pain will be evaluated by self-report through use of pain assessment scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of scarring</measure>
    <time_frame>6 weeks</time_frame>
    <description>Physical evaluation for scarring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Sexual Function</measure>
    <time_frame>Baseline (enrollment), 6 months, 12 months</time_frame>
    <description>Evaluated by Female Sexual Function Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Mental and Physical Wellness</measure>
    <time_frame>Baseline (enrollment), 6 months, 12 months</time_frame>
    <description>Evaluated by Functional Assessment of Cancer Therapy - Vulva (FACTS-V) health survey for vulva disease</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Vulvar Intraepithelial Neoplasia (VIN)</condition>
  <arm_group>
    <arm_group_label>Sonopet Ultrasonic Aspirator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of VIN dysplasia with sonopet ultrasonic aspirator: to evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CO2 Laser Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of VIN dysplasia with CO2 Laser Ablation: to evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sonopet Ultrasonic Aspirator</intervention_name>
    <description>To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation</description>
    <arm_group_label>Sonopet Ultrasonic Aspirator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CO2 Laser Ablation</intervention_name>
    <description>To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation</description>
    <arm_group_label>CO2 Laser Ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women 18-89 years old&#xD;
&#xD;
          -  Women diagnosed with high-grade VIN (diagnosed by pathology)&#xD;
&#xD;
          -  Women referred for vulva sparing treatment for dysplasia&#xD;
&#xD;
          -  Women available for follow-up of treatment for 12 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant&#xD;
&#xD;
          -  Women with low-grade VIN dysplasia (diagnosed by pathology)&#xD;
&#xD;
          -  Women with vaginal intraepithelial neoplasia(VAIN)&#xD;
&#xD;
          -  Women requiring vulvectomy for treatment&#xD;
&#xD;
          -  Women unable to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saketh Guntupalli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alyse Brennecke</last_name>
    <phone>303-724-6413</phone>
    <email>alyse.brennecke@cuanschutz.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pamela Alvarez</last_name>
    <email>OBGYNARC@cuanschutz.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyse Brennecke</last_name>
      <phone>303-724-6413</phone>
      <email>alyse.brennecke@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Saketh Guntupalli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

